Medigene generates revenue from royalties, product sales, and milestone payments with Veregen®, a drug for the treatment of genital warts. Veregen® is based on a defined extract from green tea leaves and is currently available in the USA and Canada, in 20 European countries, and in Taiwan. The market approval process for Veregen® in further European countries is completed. National market approval in important pharmaceuticals markets, such as the UK, Italy and Russia, was granted during the period under review. The successive market launch started in the UK, Ireland and Croatia in the second half of 2015. Numerous marketing agreements for Veregen® are in place with international partners (see www.medigene.com/veregen).
In 2015, Medigene concluded two additional marketing agreements: L.F. Will-Pharma & Cie, Medigene’s partner for Belgium, the Netherlands, and Luxembourg, is the new marketing partner for France. Moreover, Medigene entered into a sales and distribution partnership agreement with Litha Healthcare based in South Africa governing distribution in 13 countries in the southern half of the African continent.